NVSNovartis PharmaceuticalsRunning, no new patients
Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis
Generalized Myasthenia Gravis
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 15 (planned)
- Started
- Apr 22, 2025
- Main results expected
- Oct 26, 2029
- Fully finished
- Oct 26, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Occurrence, severity, and frequency of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Measured over: Baseline up to 2 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06704269 · record last updated 2026-09-04 · checked 2026-11-09 15:47 UTC